Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference

Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference
Atossa Therapeutics delivers Z-endoxifen update

Atossa Therapeutics delivered an oral update on its clinical trial of (Z)-endoxifen during the MDA Clinical and Scientific Conference held on March 11, 2026, in Orlando, Florida.

The presentation focused on the latest advancements in (Z)-endoxifen, a novel therapeutic approach intended for potential applications in cancer treatment. Details from the presentation are available in the company’s recent press release.

The company's update builds on a growing body of research into (Z)-endoxifen's therapeutic potential, reinforcing Atossa's long-term vision for cancer prevention as outlined in its Z-Endoxifen strategy for breast cancer prevention. The ongoing expansion of the platform, with a focus on molecular precision, further reflects progress highlighted in previous coverage of Atossa Therapeutics' advances in oncology and DMD targeting.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.